| 產(chǎn)品描述： | TMP269 is a novel and selective class IIa histone deacetylase (HDAC) inhibitor with IC50s of 157 nM, 97 nM, 43 nM and 23 nM for HDAC4, HDAC5, HDAC7 and HDAC9, respectively. |
| 靶點： |
HDAC9:23 nM (IC50);HDAC7:43 nM (IC50);HDAC5:97 nM (IC50);HDAC4:157 nM (IC50);HDAC8:42000 nM (IC50);HDAC6:82000 nM (IC50);HDAC |
| 體內(nèi)研究： |
In vivo angiogenesis assay, MDA-MB-231 cells are mixed with growth factor-reduced Matrigel and implanted subcutaneously into the flanks of nude mice. TMP269 (subcutaneous injection; 15 mg/kg; every other day; 10 days) shows an obvious antiangiogenic effect with 76% inhibition of angiogenesis in mice |
| 參考文獻： |
1. Lobera M, et al. Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group. Nat Chem Biol. 2013 May;9(5):319-25. 2. Sinnett-Smith J, et al. Protein kinase D1 mediates class IIa histone deacetylase phosphorylation and nuclear extrusion in intestinal epithelial cells: role in mitogenic signaling. Am J Physiol Cell Physiol. 2014 May 15;306(10):C961-71. 3. Kikuchi S, et al. Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. Leukemia. 2015 Sep;29(9):1918-1927. 4. EricSalgado, et al. Volume 503 HDAC9 overexpression confers invasive and angiogenic potential to triple negative breast cancer cells via modulating microRNA-206. Biochemical and Biophysical Research Communications. |
| 溶解性： |
DMSO : 100 mg/mL (194.36 mM; Need ultrasonic) |
| 保存條件： |
2-8℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
1.944 ml |
9.718 ml |
19.436 ml |
| 5 mM |
0.389 ml |
1.944 ml |
3.887 ml |
| 10 mM |
0.194 ml |
0.972 ml |
1.944 ml |
| 50 mM |
0.039 ml |
0.194 ml |
0.389 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。 |
上海工商
危險品化學品經(jīng)營許可證（不帶存儲）
營業(yè)執(zhí)照(三證合一)
北京